secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2021-11-12T23:59:59+00:00
Accession:  0001171843-21-007863
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus Biopharma appoints Tram Tran, M.D. to board of directors
----------------------------------------------------------------

- Board expanded to nine members; Dr. Tran appointed effective November 9, 2021.
- Annual cash retainer of $40,000 plus option for 44,000 shares at $3.50, vesting over 3 years.
- Dr. Tran is CMO at Glympse and former Gilead VP, with expertise in liver diseases and HBV.
- Appointment runs until the 2022 annual general meeting, subject to continued board service.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184321007863/0001171843-21-007863-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184321007863/f8k_111121.htm
  HTML page:      https://secwatch.observer/filing/0001171843-21-007863

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer